LLY - 5 Reasons Eli Lilly Just Keeps Rising

2024-06-30 11:21:10 ET

Summary

• Despite high market multiples, the Eli Lilly stock has outperformed the S&P 500 Health Care Index YTD, and this might just continue.
• Strong Q1 2024 performance leading to an upgraded guidance for the year is encouraging. The possible expansion of the remit of its diabetes and obesity treatments is another positive.
• The company's dividend growth is worth noting too, making it a continued good buy for the medium-to-long-term at the very least.

When I put a Buy rating on Eli Lilly ( LLY ) a quarter ago, I didn’t believe that it was an investment for the short-term, but that it had potential from the longer term perspective. As it happens, it turned out to be one for short-term gains too, with an over 17% increase in price since I wrote. The stock is now up by 56% year-to-date [YTD], far outstripping the just 7% rise in the S&P 500 Health Care Index in this time....

For further details see: